Navigation Links
Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Date:8/8/2008

for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 WuXi PharmaTech ... open-access R&D capability and technology platform company serving ... announced today that an Investigational New Drug (IND) ... for rheumatoid arthritis has been accepted for review ... In September 2012, MedImmune, the ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... 2015 The Market Element LLC, a ... alliance with Designing Gig LLC to provide website design, ... , “Forging this alliance with Designing Gig represents a ... extend a comprehensive, end-to-end, digital solution for our clients, ... said Chuck Miller, president of The Market Element. “For ...
(Date:3/26/2015)... Neogen Corporation (NASDAQ: NEOG ) announced ... of fiscal 2015, which ended Feb. 28, increased 13% ... Earnings per share in the current quarter were $0.20, ... income increased 17% over prior year to $24,142,000, or ... share, for the same period a year ago. ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Leader Strengthens Scaffold-Engineering Capabilities ... Electrospinning Platform Technology & Team, CANTON, Mass. ... the world,s most successful regenerative medicine,company, announced today ... NanoMatrix,s platform technology develops "designer scaffolds" for the,purposes ...
... latest Rainbow SET(R) parameter at the upcoming World ... Congress of Anesthesiologists ... inventor,of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion ... for,noninvasive and continuous total hemoglobin (SpHb(TM)) and oxygen content,(SpOC(TM)) ...
... t2cure, a clinical,stage biopharmaceutical company developing novel ... that it has appointed,Dr. Petra Rueck Head of ... Petra join our company", said Manfred Ruediger,CEO of ... will be of critical importance to t2cure as ...
Cached Biology Technology:Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc. 2Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc. 3Masimo Announces Continuous Noninvasive Total Hemoglobin 2Masimo Announces Continuous Noninvasive Total Hemoglobin 3Masimo Announces Continuous Noninvasive Total Hemoglobin 4Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... advance vaccines for related viruses including dengue fever. A ... West Nile virus has an intriguing secret: Contrary to ... to attach to host cells. Instead, the antibody somehow ... , "This was a complete surprise to us, but ...
... compound derived from cottonseed could help improve the effectiveness ... at the University of Michigan Comprehensive Cancer Center have ... issue of the journal Molecular Cancer Therapeutics, could lead ... surgically removing the cancer, helping patients preserve vital organs ...
... McKnight Brain Institute have created a system in rodent ... the process of generating new brain cells -- in ... of the National Academy of Sciences, researchers describe a ... a limitless supply of a person's own brain cells ...
Cached Biology News:Secrets to antibody's success against West Nile Virus surprise scientists 2Secrets to antibody's success against West Nile Virus surprise scientists 3Secrets to antibody's success against West Nile Virus surprise scientists 4Compound from Chinese medicine shows promise in head and neck cancer 2Compound from Chinese medicine shows promise in head and neck cancer 3For first time, brain cells generated in a dish 2For first time, brain cells generated in a dish 3
...
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: